Phase III
The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
Over the past ten years, Tonix’s pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.
Biogen exercised an option to pick up an exclusive global license for a drug to treat spinal muscular atrophy from Ionis. The compound, BIIB115, is an antisense oligonucleotide.
Today, the FDA approved two new drug applications. One is for Spero’s tebipenem HBr oral tablets and the second is CStone’s IND application for CS5001.
Applied Therapeutics said it is holding off on a New Drug Application after discussions with the FDA, which appears to require additional clinical data.
Novavax vaccine’s emergency use authorization application has been submitted to FDA recently. Novavax is hoping to bring it to the Finish Line in 2022.
Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.
Positive data from a Phase II/III trial of Bharat Biotech vaccine, Covaxin. Read more about the research and know about the efficiency of the vaccine.
In addition to the beginnings of the Jazz PTSD study, Revive announced its Phase III study of Bucillamine in patients with mild to moderate COVID-19 will continue.
PRESS RELEASES